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FTO inﬂuences adipogenesis by regulating mitotic
clonal expansion
Myrte Merkestein1,2,*, Samantha Laber1,2,*, Fiona McMurray1, Daniel Andrew1, Gregor Sachse2,
Jeremy Sanderson1, Mengdi Li1, Samuel Usher2, Dyan Sellayah1,2,w, Frances M. Ashcroft2,w & Roger D. Cox1,w
The fat mass and obesity-associated (FTO) gene plays a pivotal role in regulating body weight
and fat mass; however, the underlying mechanisms are poorly understood. Here we show that
primary adipocytes and mouse embryonic ﬁbroblasts (MEFs) derived from FTO over-
expression (FTO-4) mice exhibit increased potential for adipogenic differentiation, while
MEFs derived from FTO knockout (FTO-KO) mice show reduced adipogenesis. As predicted
from these ﬁndings, fat pads from FTO-4 mice fed a high-fat diet show more numerous
adipocytes. FTO inﬂuences adipogenesis by regulating events early in adipogenesis, during
the process of mitotic clonal expansion. The effect of FTO on adipogenesis appears to be
mediated via enhanced expression of the pro-adipogenic short isoform of RUNX1T1, which
enhanced adipocyte proliferation, and is increased in FTO-4 MEFs and reduced in FTO-KO
MEFs. Our ﬁndings provide novel mechanistic insight into how upregulation of FTO leads to
obesity.
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T
he fat mass and obesity-related gene (FTO) was the ﬁrst
gene shown to play a role in common obesity. Genome-
wide association studies identiﬁed a single-nucleotide
polymorphism (SNP) in the ﬁrst intron of the FTO gene that is
associated with body mass index in Caucasians1, and subsequent
studies conﬁrmed this ﬁnding in multiple human populations
and ethnic groups2. The increase in body mass index results
almost entirely from an increase in fat mass3–6. In vivo studies
using mouse models have also demonstrated that knockout of
FTO7–9, or a mutation in FTO that impairs its function10, leads to
reduced body weight and fat mass. Conversely, overexpression of
FTO results in increased body weight and fat mass11. Recently, it
has been proposed that the obesity-related SNPs in FTO inﬂuence
obesity susceptibility not by affecting FTO gene expression, but by
altering the expression of the adjacent genes IRX3 and
RPGRIP1L12,13. Other studies, however, have linked the SNP
risk genotype to increased FTO expression in human ﬁbroblasts
and blood cells14,15. Furthermore, the mouse data strongly
support a role for FTO in regulating body weight and fat mass,
and a mutation in the catalytic domain of FTO (R316Q) in
humans results in a severe phenotype accompanied by growth
retardation16. Thus, although the intronic SNPs may operate via
different mechanisms, FTO clearly plays a role in the regulation of
fat mass.
The mechanism by which FTO affects fat mass has been
elusive. FTO is a nucleic acid demethylase that removes methyl
groups from both DNA and RNA17–19. It is commonly thought
that its most important functional role is demethylating
N6methyladenosine (m6A)19, which thereby could regulate
processing, stability and alternative splicing of mRNAs20–22. A
recent study of 3T3-L1 cells supports this idea, showing that FTO
controls mRNA splicing by regulating the ability of the splicing
factor SRSF2 to bind mRNA in an m6A-dependent way22. One of
the targets of SRSF2 is Runt-related transcription factor 1
(RUNX1T1), an adipogenesis-related transcription factor that
exists in two splice variants, a long (L) and a short (S) isoform.
Overexpression of the S isoform of RUNX1T1 in 3T3-L1 cells
stimulates adipogenesis, suggesting that FTO might act via
RUNX1T1 to enhance adipocyte formation22. We therefore
explored whether FTO modulates adipogenesis in native cells
derived from mice overexpressing FTO11 or in which FTO had
been deleted8. Our data provide ﬁrm evidence that FTO regulates
adipocyte differentiation in vivo and that this is the mechanism
by which FTO affects fat mass. Furthermore, we show that FTO
acts early in adipogenesis, during mitotic clonal expansion
(MCE), to enhance adipocyte number.
Results
FTO promotes adipogenesis in vitro. Mouse embryonic ﬁbro-
blasts (MEFs) from mice in which FTO was either deleted (FTO-
KO7,8) or overexpressed (FTO-4 (ref. 11)) were induced to
differentiate into mature adipocytes by treatment with an
adipogenic induction cocktail containing dexamethasone, IBMX
and insulin. MEFs derived from FTO-KO mice exhibited reduced
adipogenic capacity, as measured with Oil Red-O staining for
triglycerides (Fig. 1a) and light microscopy (Fig. 1b). Quantitative
analysis using quantitative PCR (qPCR) showed that this was
associated with a reduction in the mRNA levels of FABP4,
PPARg, C/EBPa and PLIN1 (Fig. 1c), genes that play a critical role
in adipogenesis. Protein expression of FABP4 and PLIN1 was also
lower in FTO-KO MEFs than in wild-type (WT) MEFs
(Supplementary Fig. 1).
Overexpression of FTO produced the opposite result. Follow-
ing adipogenic induction, primary preadipocytes from the
supravascular fraction of gonadal white adipose tissue (gWAT)
of FTO-4 mice exhibited strikingly greater triglyceride accumula-
tion than WT mice (Fig. 1d–f). Expression of the adipogenic
genes FABP4, PPARg and PLIN1 was 50-, 55- and 70-fold,
respectively, greater in FTO-4 than in WT preadipocytes (Fig. 1g).
Furthermore, protein expression of FABP4 was higher in FTO-4
MEFs than in WT MEFs (Supplementary Fig. 2). To conﬁrm that
these pro-adipogenic changes were FTO-dependent, we knocked
down FTO by short interfering RNA (siRNA) in primary
preadipocytes from gWAT of FTO-4 mice (Supplementary
Fig. 3). This attenuated triglyceride accumulation (Fig. 1h) and
signiﬁcantly reduced adipogenic gene expression (Fig. 1i) when
compared with preadipocytes treated with control siRNA.
As it has been proposed that IRX3 and RPGRIP1L are primarily
responsible for the enhanced obesity associated with the obesity-
related SNPs in FTO12,13, we compared mRNA levels of FTO,
IRX3 and RPGRIP1L in WT gWAT and MEFs. Levels of IRX3
and RPGRIP1L were considerably lower than that of FTO in both
gWAT and MEFs of WT mice. Further, FTO expression was 13-
fold higher than that of RPGRIP1L and over 1,000-fold higher
than that of IRX3 in gWAT of WT mice (Supplementary Fig. 4).
Importantly, we did not observe any signiﬁcant differences in
IRX3 or RPGRIP1L gene expression in FTO-4 MEFs
(Supplementary Fig. 5a), FTO-KO MEFs (Supplementary
Fig. 5b) or FTO-4 gWAT (Supplementary Fig. 5c), when
compared with WT MEFs and gWAT of WT mice. These data
provide evidence that the effects of FTO overexpression and
knockdown on adipogenesis are independent of either IRX3 or
RPGRI1PL.
FTO regulates MCE in a demethylation-dependent manner. We
observed that FTO affects adipogenesis by inﬂuencing events
early in the adipogenic programme. Supplementary Fig. 6 shows
that 3 days after adipogenic induction PPARg gene expression
was signiﬁcantly higher in FTO-4 MEFs than WT controls, and
both PPARg and FABP4 gene expression were lower in FTO-KO
MEFs than in WT controls. Expression of FTO itself is also
regulated during adipogenesis, being stable during the ﬁrst 48 h
after induction and then declining dramatically (Supplementary
Fig. 7), as has been shown before23,24.
We next measured MCE, using 5-bromodeoxyuridine (BrdU)
incorporation to assess cell proliferation. Twenty-four hours after
induction of adipogenesis, FTO-KO MEFs showed less prolifera-
tion than WT MEFs (Fig. 2a,b). Conversely, FTO-4 MEFs
displayed greater proliferation than WT MEFs (Fig. 2c,d). These
differences do not originate in alterations in cell survival/death, as
no differences in cell death were found between WT and FTO-4
MEFs, or between WT and FTO-KO MEFs (Supplementary
Fig. 8). Knockdown of FTO in FTO-4 MEFs by siRNA, before
stimulation with the adipogenic cocktail, attenuated BrdU
incorporation, conﬁrming the central role of FTO in adipogenesis
(Supplementary Fig. 9).
To determine when FTO acts to regulate adipogenesis, we next
knocked down FTO in FTO-4 MEFs 48 h after adipogenic
induction. While FTO knockdown before adipogenic induction
reduced the expression of PPARg, FABP4 and C/EBPa (Figs 1c,h
and 2e), FTO knockdown after MCE had no effect on adipogenic
gene expression on day 7 (Fig. 2f). Thus, FTO exerts its effects
early in adipogenesis, during the MCE phase. To further assess
the involvement of FTO in MCE, we studied its effects on the
expression of CCND1 and CCND3, two cyclin genes that are
important for cell cycle progression25. Both these genes are
upregulated by induction of adipogenesis (Fig. 2g,h). Transfection
of FTO-4 MEFs with FTO siRNA led to a signiﬁcant
downregulation of both CCND1 (Fig. 2g) and CCND3 (Fig. 2h)
at 24 h (CCDN1) and 40 h (CCDN3) after adipogenic induction
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when compared with FTO-4 MEFs transfected with control
siRNA. Conversely, overexpression of FTO in WT MEFs caused a
signiﬁcant upregulation of CCND1 expression 24 h following
adipogenic induction (Supplementary Fig. 10).
We next examined whether the demethylase activity of FTO is
required for its effects on adipocyte proliferation. We over-
expressed WT FTO or a catalytically inactive FTO (R313A) in
FTO-KO MEFs and compared BrdU staining 24 h after
adipogenic induction. FTO-R313A is the mouse equivalent of
human R316A, which lacks catalytic activity17. Figure 3 shows
that MEFS transfected with WT FTO, but not with the vector
alone, showed enhanced proliferation. In contrast, transfection
with FTO-R313A did not increase proliferation (Fig. 3). These
results demonstrate that intact demethylation activity is necessary
for the effect of FTO on MCE.
FTO might exert its effects on MCE by acting through
RUNX1T1. It has been suggested that deletion of FTO attenuates
adipogenesis by inhibition of the pro-adipogenic S isoform of
RUNX1T1 (ref. 22). To evaluate this possibility, we ﬁrst analysed
expression of the S and L isoforms of RUNX1T1 in FTO-4 and
FTO-KO MEFs. We found that RUNX1T1-L was expressed at
much higher levels than RUNX1T1-S in MEFs. Our results
revealed a decrease in RUNX1T1-S in FTO-KO MEFs (Fig. 4a).
However, we observed that FTO overexpression was associated
with a clear increase in RUNX1T1-S (Fig. 4b). The L isoform of
RUNX1T1 was downregulated in FTO-KO MEFs, but to a lesser
extent than the S isoform, and no difference was observed in
RUNX1T1-L when FTO was overexpressed. Thus, the S isoform
of RUNX1T1 appears to play a greater role in adipogenesis than
the L isoform.
We next knocked down RUNX1T1 in WT MEFs using siRNA
(Fig. 4c) and compared cell proliferation (BrdU staining) with
that found for WT MEFs transfected with control siRNA.
Knockdown of RUNX1T1 reduced proliferation, measured 24 h
after adipogenic induction (Fig. 4d,e). It also prevented the
upregulation of CCND1 and CCND3 in response to induction of
adipogenesis (Fig. 4f,g). These results provide strong support for a
role for RUNX1T1-S in MCE.
Taken together, our results show that FTO promotes
adipogenesis by activating MCE and suggest that this effect is
dependent on its catalytic activity. Furthermore, the data are
consistent with the idea that FTO mediates its effect by enhancing
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Figure 1 | FTO overexpression promotes adipogenesis, while FTO deletion inhibits adipogenesis in vitro. (a) Triglyceride uptake (Oil Red-O staining),
(b) morphology (brightﬁeld microscopy; scale bar, 50mM) and (c) qPCR for mRNA of adipogenic genes in MEFs from WT and FTO-KO mice 7 days after
adipogenic induction. (d) Triglyceride uptake (Oil Red-O staining), (e) microscopic images of Oil Red-O stain; scale bar, 20mM, (f) morphology (brightﬁeld
microscopy; scale bar, 50mM, (g) qPCR of adipogenic genes 7 days after adipogenic induction in WT and FTO-4 primary preadipocytes. (h) Triglyceride
uptake (Oil Red-O staining), (i) and qPCR of adipogenic genes, 7 days after onset of adipogenic differentiation in primary preadipocytes from FTO-4 mice
treated with control (black) or FTO (green) siRNA. (a–c) Data represent three biological replicates each with three technical replicates. (d–f) Data represent
three experiments on preadipocytes from one mouse of each genotype. (g,h) Data represent three experiments on preadipocytes from one mouse.
Data presented in graphs represent means±s.e.m.. (c,f,h) Multivariate ANOVA with Bonferroni post hoc analysis. *Po0.05; **Po0.01; ***Po0.001.
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expression of the S form of RUNX1T1. To examine the
physiological relevance of FTO-dependent adipogenesis, we next
investigated whether this regulation contributes to the increased
fat mass observed in mice overexpressing FTO.
Mice overexpressing FTO exhibit increased gWAT hyperplasia.
Female mice overexpressing FTO (FTO-4) on a C57BL/6J back-
ground gained signiﬁcantly more weight than WT mice when
given a normal chow diet (Supplementary Fig. 11a). These
differences became more obvious when mice were fed a high-fat
diet (HFD; 45% kcal fat) between 17 and 28 weeks of age
(Supplementary Fig. 11a). Differences in body weight between WT
and FTO-4 mice were predominantly due to fat mass (Supple-
mentary Fig. 11b), as lean mass remained similar between groups
(Supplementary Fig. 11c). These results conﬁrm previous studies
showing that a HFD results in a greater increase in body weight
and adiposity in FTO-4 than in WT mice11.
To test whether adipose tissue hyperplasia is responsible for the
elevated fat mass of FTO-4 mice, we carried out histological
0h 16
h
24
h
40
h
0.0
0.5
1.0
1.5
2.0
Time post differentiation
FTO-4 siCON
FTO-4 siFTO
*
0h 16
h
24
h
40
h
0.0
0.5
1.0
1.5
Time post differentiation
CC
ND
3 
ex
pr
es
sio
n 
re
la
tiv
e
to
 G
AP
DH
FTO-4 siCON
FTO-4 siFTO
*
FTO-4WT
FTO-KOWT 8
*
6
4
2
0
%
 B
rd
u-
po
sit
ive
 c
el
ls 
15
***
WT FTO-4
10
5
0
%
 B
rd
U-
po
sit
ive
 c
el
ls 
G
en
e 
ex
pr
es
io
n 
re
la
tiv
e
to
 G
AP
DH
G
en
e 
ex
pr
es
io
n 
re
la
tiv
e
to
 G
AP
DH
CC
ND
1 
ex
pr
es
io
n 
re
la
tiv
e
to
 G
AP
DH
1.5
FTO-4 siCON
FTO-4 siFTO
1.0
*
* *
0.5
0.0
2.5
FTO-4 siCON
FTO-4 siFTO
2.0
1.5
1.0
0.5
0.0
FABP4 PPARγ C/EBPαFABP4 PPARγ C/EBPα
WT FTO-KO
Figure 2 | FTO promotes adipogenesis via mitotic clonal expansion. (a) Representative image showing BrdU incorporation, 24 h after induction of
adipogenic differentiation in MEFs from WT and FTO-KO mice, BrdU (green), DAPI (blue); scale bar, 100mM. (b) Quantiﬁcation analysis of BrdU
incorporation in WTversus FTO-KO MEFs. (c) Representative image showing BrdU incorporation, 24 h after induction of adipogenic differentiation in MEFs
from WT and FTO-4 mice, BrdU (green), DAPI (blue); scale bar, 50mM. (d) Quantiﬁcation analysis of BrdU incorporation in WT versus FTO-4 MEFs.
(c,d) Data represent six experiments using MEFs derived from one mouse of each genotype. (e,f) qPCR of mRNA for the indicated genes in FTO-4 MEFs
treated with control (black) or FTO (green) siRNA before (e) or 48 h after (f) adipogenic induction. Data are expressed relative to expression of GAPDH.
Data represent three experiments each with three technical replicates on MEFs from one mouse. (g,h) qPCR of mRNA for CCND1 (g) and CCND3 (H) in
FTO-4 MEFs treated with control (black) or FTO (green) siRNA, at 16, 24 and 40h after induction of adipogenic differentiation. Data represent 1 (0 h) or 4
(16, 24 and 40 h) biological replicates each with three technical replicates. Independent Students’ t-test (c,d), multivariant ANOVA (e,f), repeated-
measures ANOVA (g,h). *Po0.05; ***Po0.001 against WT (c,d) or control (e–h). Data presented in graphs represent means±s.e.m.
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analyses of gWAT of WT and FTO-4 mice, both at weaning
(4 weeks of age) and after 8 weeks of a HFD initiated at weaning
(12 weeks of age). At weaning, gWAT from WT and FTO-4 mice
did not differ in morphology when observed with haematoxylin
and eosin (H&E) staining (Fig. 5a). After 8 weeks of HFD,
however, FTO-4 mice had smaller but more numerous adipocytes
than WT mice (Fig. 5a). Quantitative image analysis of adipocyte
volume revealed that as many as 25% of cells in FTO-4 gWAT
had cell volumes below 0.25mm3, compared with 8% of WT
gWAT cells after 8 weeks of HFD (Fig. 5b). Analysis of total
adipocyte number revealed a signiﬁcantly greater cell number in
FTO-4 gWAT (0.45 million adipocytes) than WT gWAT (0.17
million adipocytes) after 8 weeks of HFD (Fig. 5c). The greater
number of adipocytes in gWAT of FTO-4 mice given a HFD is
consistent with the enhanced proliferation of FTO-4 MEFs
following induction of adipogenesis.
After HFD feeding for 8 weeks, gWAT from FTO-4 mice also
expressed higher levels of PPARg and C/EBPa mRNAs than WT
mice. No such difference was found immediately after weaning
(Fig. 5d,e). There were no signiﬁcant differences in gWAT depot
weights at weaning between WT and FTO-4 mice, or after 8
weeks of high-fat feeding (Supplementary Fig. 12). The latter may
be attributed to the facts that the adipocytes in FTO-4 mice are
not only more numerous but also smaller, and that expansion of
adipocyte size is a feature usually observed for HFD feeding of
longer than 2 months26.
Taken together, our results indicate that FTO overexpression is
associated with increased adipogenic capacity, through the
increased activation of MCE. These effects are potentially
mediated through the relative increase in the pro-adipogenic S
isoform of RUNX1T1. This is summarized in a schematic
diagram (Fig. 6).
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Discussion
Our study provides strong evidence that FTO regulates adipogen-
esis and thereby inﬂuences fat mass and body weight. We show
that enhanced FTO activity increased adipogenesis, whereas
decreased FTO activity inhibited adipocyte formation, in both
MEFs and primary preadipocytes from genetically modiﬁed mice.
Furthermore, as predicted from these in vitro studies, high-fat
feeding in mice overexpressing FTO induced adipocyte hyperplasia.
Our results demonstrate that FTO is a critical regulator of
adipogenesis in mice that acts in the early stages of adipogenesis.
MCE is a prerequisite for adipocyte differentiation that occurs
within 48 h of adipogenic stimulation. During MCE, growth-
arrested preadipocytes and MEFs re-enter the cell cycle and
undergo two rounds of proliferation. The transcription factor C/
EBPb gains the capacity to bind DNA, which leads to the
upregulation of PPARg and CEBPa, the master regulators of
adipogenesis27. This is accompanied by initiation of a
transcriptional cascade that results in terminal adipogenic
differentiation28–30 (Fig. 6). We found that FTO knockdown
inhibits adipogenesis but only before MCE, and that FTO
overexpression, as expected if it induces MCE, leads to
expression of PPARg and CEBPa.
Our data support the idea that FTO acts by regulating the
splicing of the adipogenesis-related transcription factor RUNX1T1
(ref. 22). We show that FTO regulates expression of the S isoform of
RUNX1T1 in MEFs. In contrast, expression of RUNX1T1-S was
reduced in MEFs from FTO-KO mice and, importantly, was
increased in MEFs from mice overexpressing FTO. Furthermore,
knockdown of RUNX1T1 in WT MEFs reduced cell proliferation
and expression of cell cycle genes during MCE.
Previous studies in 3T3-L1 cells have shown that over-
expression of the L isoform of RUNX1T1 impairs adipogen-
esis22,31, and, conversely, that overexpression of the S isoform of
RUNX1T1 enhances adipogenesis22. The effect of RUNX1T1 on
adipocyte differentiation and proliferation will therefore be
determined by the balance between the L and S isoforms of
RUNX1T1. Earlier studies that did not differentiate between the L
and S isoforms found that overexpression of RUNX1T1 inhibited
adipogenesis by binding of RUNX1T1 to C/EBPb and thereby
preventing its DNA-binding activity and the transcriptional
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Figure 5 | FTO overexpression promotes adipogenesis in vivo. (a) Light microscope images ( 20 magniﬁcation) of haematoxylin/eosin-stained gWAT
from WT (left) and FTO-4 (right) mice after weaning (top, WT, n¼ 3, FTO-4, n¼ 5) and after 8 weeks of HFD following weaning (bottom, WT, n¼4, FTO-
4, n¼ 3), scale bars, 50mM. (b,c) Distribution of adipocyte volume (b) and adipocyte number (c) in gWATof WT (black, n¼4) and FTO-4 (purple, n¼ 3)
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cascade that results in adipocyte formation31. Given that the L
isoform of RUNXT1 is found at much higher levels than the S
isoform in 3T3-L1 cells22, it seems likely that this effect is due to
the predominance of RUNXT1-L. How the S isoform stimulates
the adipogenic cascade remains an open question—but an
obvious possibility is that it binds to, and activates, C/EBPb.
Interestingly, FTO has been shown to act as a transcriptional co-
activator of C/EBPb (ref. 32).
It is important to recognize that knockdown of RUNX1T1 will
result in the loss of both S and L isoforms. Because knockdown
leads to reduced cell proliferation, this favours the idea that the
effect of the S form is dominant both in MEFs (this paper) and
microglia33. Our data therefore support the role of the FTO/
RUNX1T1 interaction in modulating adipogenesis recently
reported in ref. 22 and, further, show that this interaction
inﬂuences the MCE stage of adipogenesis.
While it remains controversial as to whether the obesity-related
SNPs in FTO act via modulation of FTO function or by
inﬂuencing adjacent genes such as IRX3 and RPGRIP1L, our
results provide ﬁrm evidence that FTO modulates adipogenesis,
and thereby fat mass, both in vitro and in vivo.
Our in vivo studies focus on the response to high-fat feeding.
Adipose expansion in mice in response to HFD feeding can be
produced by both hypertrophy (increased cell size) and
hyperplasia (increased cell number), with the relative predomi-
nance of each depending on the fat depot26. Whereas
hypertrophy predominates in the ﬁrst month of HFD feeding
in WT mice, HFD feeding beyond this time results in hyperplasia,
which becomes the predominant means by which gWAT expands
at 2 months26. Although there were no differences in gWAT
adipocyte number between WT and FTO-4 mice at weaning
(4 weeks of age), after 8 weeks of a HFD gWAT cell number in
FTO-4 mice was much greater than that of WT mice. Our data
further suggest that in FTO-4 mice, the increase in the size of fat
cells may be slightly delayed with respect to WT, as after 2
months of a HFD FTO-4 adipocytes were smaller, as well as more
numerous, than those of WT mice. A previous study has shown
greatly increased adipocyte size after 30 weeks of HFD in gWAT
from FTO-4 mice compared with WT mice11.
In contrast to a previous study26, we did not observe a
signiﬁcant increase in adipocyte number in response to 2 months
of high-fat feeding in WT mice. This difference may be
attributable to differences in the fat content of the different
diets: 45% kcal as fat in our study compared with 60% kcal as fat
in the previous study26. Furthermore, in our study, mice were
started on a HFD at 4 weeks of age compared with 10 weeks of
age in the previous study. We cannot rule out the possibility that
gWAT hyperplasia might also occur on a chow diet, particularly
in light of previous studies showing increased adiposity in FTO-4
versus WT mice maintained on a chow diet11.
Although it is still unclear whether any of the known intronic
SNPs in FTO can modulate FTO expression, our data have
implications for humans carrying gain-of-function variants in
FTO. They suggest that such individuals might show enhanced
adipogenesis, especially on a diet high in fat. Furthermore, fat
cells induced by a HFD can be expected to remain even after
reverting to a less caloriﬁc diet. This would lead to an enhanced
storage capacity and a greater propensity for increased fat mass
and body weight when energy consumption exceeds energy
expenditure.
Methods
Ethical statement. Animal studies were conducted in accordance with the UK
Animals (Scientiﬁc Procedures) Act (1986). All mice were maintained in accor-
dance with the UK Home Ofﬁce Welfare guidelines and project licence restrictions.
All studies were approved by the local Animal Welfare and Ethical Review Body at
MRC Harwell, under the ethical guidelines issued by the Medical Research Council
(Responsibility in the Use of Animals for Medical Research, July 1993).
Mouse studies. Mice constitutively expressing two additional copies of FTO in all
tissues on a C57BL/6J background (FTO-4) were generated by insertion of the FTO
cDNA into a pCAGGs-STOP-EGFP-ROSA-TV plasmid (downstream of the STOP
cassette). Targeted stem cell injections were given to C57BL/6J blastocysts to
generate chimeras that transmitted the targeted allele when crossed to C57BL/6J
mice. F1 mice were crossed to a line carrying the b-actin-Cre recombinase (Jackson
Laboratory, stock name Tg(ACTA1-cre)79Jme/J) on a C57BL/6J background, and
the offsprings were backcrossed again to C57BL/6J to remove Cre recombinase.
These mice were then intercrossed in multiple different matings to generate the test
populations. WT C57BL/6J littermates were used as controls. All experiments were
carried out on female mice maintained in a temperature- (21±2 C) and humidity
(55±10%)-controlled room on a 12:12 light dark cycle (light 0700–1900 h). Mice
had ad libitum access to water (9–13 p.p.m. chlorine) and food (SDS Rat and
Mouse No. 3 Breeding diet (RM3) containing 11.5 kcal% fat, 23.9 kcal% protein
and 61.6 kcal% carbohydrate). When indicated, mice were maintained on a HFD
(D12451, Research Diets, New Brunswick, NJ) containing 45 kcal% fat, 20 kcal%
protein and 35 kcal% carbohydrate. Body composition was measured with an Echo
MRI whole-body composition analyzer (Echo Medical System, Houston, TX).
Histology. Serial sections of ﬁxed gWAT of WT and FTO-4 mice were stained
with H&E. ImageJ was used to determine the mean cell volume per section. Total
adipocyte number was determined by using the equation: n¼m (depot mass g)/P
(density of adipose 0.915 g cm 3)  volume (cm3) as previously described34.
MEFs. To obtain MEFs, timed matings of FTO-3 mice (to obtain FTO-4 embryos)
or heterozygous FTO-KO mice (to obtain FTO-KO embryos) were set up. WT
littermate embryos were used as controls. Mothers were killed at E12.5 E14.5 and
embryos collected. Following removal of the head, liver and blood clots, individual
embryos were dissociated in 0.25% Trypsin (Gibco, Paisley, Scotland) and subse-
quently triturated. MEFs were cultured at 37 C and 5% CO2 in DMEM (Gibco)
supplemented with 10% fetal bovine serum and 1 penicillin/streptomycin
(Gibco). The heads of the embryos were used for DNA extraction and genotyping.
Primary adipocyte culture. Primary adipocytes were isolated from dissected
gWAT of 12-week-old mice and digested with collagenase (Sigma) in Krebs-Ringer
HEPES buffer at 37 C for 1 h. The digested tissue was ﬁltered, and was then
centrifugated to obtain the supravascular fraction, which was resuspended and
cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum and 1
penicillin/streptomycin (Gibco). Adipogenic differentiation was induced by sup-
plementing the tissue culture medium with 250 mM IBMX, 0.1 mM dexamethasone
and 0.5 mgml 1 insulin for 4 days. After this period, the culture medium was
supplemented with insulin only.
Knockdown of FTO or RUNX1T1 in cell lines was achieved using
Lipofectamine RNAiMAX (Invitrogen, CA, USA) using siRNA directed against
mouse FTO (50-CCUGCGAUGAUGAAGUGGACCUUAA-30 (Invitrogen)),
mouse RUNX1T1 (no. 161027, Invitrogen) and stealth RNA interference siRNA
Negative Control Medium GC (Invitrogen) as a control. To overexpress FTO, cells
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RUNX1T1-S
CEBPβ ?
PPARγ
CEBPα
FABP4
PLIN1
Cyclin D1
Cyclin D3
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Figure 6 | Schematic overview of the proposed role of FTO in
adipogenesis. FTO increases the relative expression of the pro-adipogenic
RUNX1T1-S isoform, which stimulates mitotic clonal expansion through
stimulating an increase in D-type Cyclin gene expression. This stimulation
of mitotic clonal expansion by FTO leads to the promotion of adipogenesis,
the de novo formation of adipocytes from ﬁbroblasts and adipocyte
precursors (preadipocytes).
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were transfected using Lipofectamine2000 (Invitrogen) with either a pcDNA3.1
vector containing full-length mouse FTO cDNA, R313A full-length mouse FTO
cDNA or an empty pcDNA3 vector as a control. Cell viability after transfection was
assessed using the LIVE/DEAD viability/cytotoxicity kit (Life Technologies).
Oil Red-O staining. Cells were washed with PBS and then ﬁxed in 10% buffered
formalin for 1 h at room temperature. After washes in PBS, cells were stained for
30min at room temperature with a ﬁltered Oil Red-O (Sigma) solution (0.5% Oil
Red-O in isopropyl alcohol), washed again in PBS and visualized under an inverted
microscope (Olympus).
BrdU analysis. To examine proliferation, a BrdU incorporation assay was
performed using a FLUOS In situ detection kit (Roche) on at least six technical
replicates. BrdU was added 24h after the onset of adipogenic differentiation for
30–45min. Immunodetection of BrdU was carried out following the manufacturer’s
instructions. Cells were also stained with 4,6-diamidino-2-phenylindole (DAPI) to
enable nuclear detection. A blinded analysis of percentage of BrdU-positive cells
(of total number of cells assessed with DAPI) was performed with ImageJ.
RNA extraction, RT–PCR experiments, protein extraction and western blot
analysis were carried out as described before11. Expression of the two different
isoforms of RUNX1T1 was measured as described in ref. 22.
RNA extraction and cDNA synthesis. Total RNA from MEFs, primary adipo-
cytes and dissected fat pads was extracted using an RNeasy Mini Plus Kit (Qiagen,
USA) according to the manufacturer’s protocol. The RNA concentration was
measured with a NanoDrop spectrophotometer (Thermo Scientiﬁc), and 1 mg of
RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems).
RT–PCR analysis. Gene expression was analysed using the TaqMan system (all
probes and reagents from Life Technologies) on a ABI Prism 7700 Sequence
Detection System (Perkin Elmer). Samples were measured in duplicate and gene
expression was normalized to the expression of glyceraldehyde-3-phosphate
dehydrogenase (Gapdh).
Western blot analysis. MEFs were harvested using the Qiagen kit with protease
inhibitors. Samples were kept on ice for at least 20min, after which nonsoluble
material was pelleted at 20,000g for 20min at 4 C. The supernatant was removed
and protein concentrations were estimated using the Bio-Rad Dc Protein assay.
For western blot analysis, 20 mg of the protein lysates were run on 4–12% Bis-
Tris SDS–PAGE gels (NuPAGE Novex, Invitrogen) and transferred to
nitrocellulose membranes. Membranes were blocked for 1 h at room temperature
in 5% milk in TBS-T, and incubated overnight at 4 C with primary antibodies to
FABP4 (Cell Signaling), PLIN1 (Cell Signaling) and HSC70 (Abcam, ab19136) as
an internal control. Blots were washed in TBS-T and incubated with secondary
antibody (horseradish peroxidase (HRP)-anti-rabbit IgG for FABP4 and PLIN1,
HRP-anti-rat IgG for HSC70, GE Healthcare) for 1 h at room temperature. After
washing, bands were visualized with enhanced chemiluminescence reagent
(SuperSignal West Pico, Pierce) and X-Ray ﬁlm. Protein density was analysed using
the ImageJ software (National Institutes of Health, USA). All primary antibodies
used were at 1:1000, and all secondary antibodies were at 1:2500 dilutions.
Data analysis. All experiments were conducted on at least three biological
replicates, each of which had at least three technical replicates, unless otherwise
stated. All values are expressed as mean±s.e.m. Unless otherwise stated, qPCR
data are normalized to GAPDH and expressed relative to WT (or control). Sta-
tistical analysis was performed using the IBM SPSS software (version 20) using
either an independent Student’s t-test or a multivariate analysis of variance
(ANOVA) with Bonferroni post hoc analysis. Parameters measured over multiple
time points were analysed with a repeated-measures ANOVA with time as a
within-subject factor. In case of a signiﬁcant group or time group interaction, a
multivariate ANOVA was run per time point to identify statistically signiﬁcant
differences. Statistical signiﬁcance was taken as Po0.05.
References
1. Frayling, T. M. et al. A common variant in the FTO gene is associated with
body mass index and predisposes to childhood and adult obesity. Science 316,
889–894 (2007).
2. Loos, R. J. & Yeo, G. S. The bigger picture of FTO-the ﬁrst GWAS-identiﬁed
obesity gene. Nat. Rev Endocrinol. 10, 51–61 (2014).
3. Kilpelainen, T. O. et al. Genetic variation near IRS1 associates with reduced
adiposity and an impaired metabolic proﬁle. Nat. Genet. 43, 753–760 (2011).
4. Renstrom, F. et al. Replication and extension of genome-wide association study
results for obesity in 4923 adults from northern Sweden. Hum. Mol. Genet. 18,
1489–1496 (2009).
5. Wardle, J. et al. Obesity associated genetic variation in FTO is associated with
diminished satiety. J. Clin. Endocrinol. Metab. 93, 3640–3643 (2008).
6. Fox, C. S. et al. Genome-wide association for abdominal subcutaneous and
visceral adipose reveals a novel locus for visceral fat in women. PLoS Genet. 8,
e1002695 (2012).
7. Fischer, J. et al. Inactivation of the FTO gene protects from obesity. Nature 458,
894–898 (2009).
8. McMurray, F. et al. Adult onset global loss of the FTO gene alters body
composition and metabolism in the mouse. PLoS Genet. 9, e1003166 (2013).
9. Gao, X. et al. The fat mass and obesity associated gene FTO functions in the
brain to regulate postnatal growth in mice. PLoS ONE 5, e14005 (2010).
10. Church, C. et al. A mouse model for the metabolic effects of the human fat
mass and obesity associated FTO gene. PLoS Genet. 5, e1000599 (2009).
11. Church, C. et al. Overexpression of FTO leads to increased food intake and
results in obesity. Nat. Genet. 42, 1086–1092 (2010).
12. Smemo, S. et al. Obesity-associated variants within FTO form long-range
functional connections with IRX3. Nature 507, 371–375 (2014).
13. Stratigopoulos, G. et al.Hypomorphism for RPGRIP1L, a ciliary gene vicinal to the
FTO locus, causes increased adiposity in mice. Cell Metab. 19, 767–779 (2014).
14. Karra, E. et al. A link between FTO, ghrelin, and impaired brain food-cue
responsivity. J. Clin. Invest. 123, 3539–3551 (2013).
15. Berulava, T. & Horsthemke, B. The obesity-associated SNPs in intron 1 of the
FTO gene affect primary transcript levels. Eur. J. Hum. Genet. 18, 1054–1056
(2010).
16. Boissel, S. et al. Loss-of-function mutation in the dioxygenase-encoding FTO
gene causes severe growth retardation and multiple malformations. Am. J.
Hum. Genet. 85, 106–111 (2009).
17. Gerken, T. et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-
dependent nucleic acid demethylase. Science 318, 1469–1472 (2007).
18. Jia, G. et al. Oxidative demethylation of 3-methylthymine and 3-methyluracil in
single-stranded DNA and RNA by mouse and human FTO. FEBS Lett. 582,
3313–3319 (2008).
19. Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the
obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 (2011).
20. Meyer, K. D. et al. Comprehensive analysis of mRNA methylation reveals
enrichment in 3’ UTRs and near stop codons. Cell 149, 1635–1646 (2012).
21. Dominissini, D. et al. Topology of the human and mouse m6A RNA
methylomes revealed by m6A-seq. Nature 485, 201–206 (2012).
22. Zhao, X. et al. FTO-dependent demethylation of N6-methyladenosine regulates
mRNA splicing and is required for adipogenesis. Cell Res. 24, 1403–1419 (2014).
23. Wahlen, K., Sjolin, E. & Hoffstedt, J. The common rs9939609 gene variant of
the fat mass- and obesity-associated gene FTO is related to fat cell lipolysis.
J. Lipid Res. 49, 607–611 (2008).
24. Tews, D., Fischer-Posovszky, P. & Wabitsch, M. Regulation of FTO and FTM
expression during human preadipocyte differentiation. Horm. Metab. Res. 43,
17–21 (2011).
25. Hishida, T., Naito, K., Osada, S., Nishizuka, M. & Imagawa, M. Crucial roles of
D-type cyclins in the early stage of adipocyte differentiation. Biochem. Biophys.
Res. Commun. 370, 289–294 (2008).
26. Wang, Q. A., Tao, C., Gupta, R. K. & Scherer, P. E. Tracking adipogenesis
during white adipose tissue development, expansion and regeneration. Nat.
Med. 19, 1338–1344 (2013).
27. Tang, Q. Q. & Lane, M. D. Adipogenesis: from stem cell to adipocyte. Annu.
Rev. Biochem. 81, 715–736 (2012).
28. Tang, Q. Q., Otto, T. C. & Lane, M. D. Mitotic clonal expansio: a
synchronous process required for adipogenesis. Proc. Natl Acad. Sci. USA 100,
44–49 (2003).
29. Tang, Q. Q., Otto, T. C. & Lane, M. D. CCAAT/enhancer-binding protein beta
is required for mitotic clonal expansion during adipogenesis. Proc. Natl Acad.
Sci. USA 100, 850–855 (2003).
30. Zhang, J. W., Tang, Q. Q., Vinson, C. & Lane, M. D. Dominant-negative C/EBP
disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes.
Proc. Natl Acad. Sci. USA 101, 43–47 (2004).
31. Rochford, J. J. et al. ETO/MTG8 is an inhibitor of C/EBPbeta activity and a
regulator of early adipogenesis. Mol. Cell Biol. 24, 9863–9872 (2004).
32. Wu, Q., Saunders, R. A., Szkudlarek-Mikho, M., Serna Ide, L. & Chin, K. V. The
obesity-associated Fto gene is a transcriptional coactivator. Biochem. Biophys.
Res. Commun. 401, 390–395 (2010).
33. Baby, N., Li, Y., Ling, E. A., Lu, J. & Dheen, S. T. Runx1t1 (Runt-related
transcription factor 1; translocated to, 1) epigenetically regulates the pro-
liferation and nitric oxide production of microglia. PLoS ONE 9, e89326 (2014).
34. Jo, J. et al. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth.
PLoS Comput. Biol. 5, e1000324 (2009).
Acknowledgements
We thank the Mary Lyon Centre staff for animal care and Christopher Church for
generating the FTO-4 mice. We thank the Wellcome Trust (093136) and the MRC for
support. S.L. and F.M. were supported by MRC PhD studentships. D.S. holds an EPA
Cephalosporin Junior Research Fellowship at Linacre College, Oxford. F.M.A. holds a
Royal Society/Wolfson Merit Award.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7792
8 NATURE COMMUNICATIONS | 6:6792 | DOI: 10.1038/ncomms7792 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Author contributions
S.L. and M.M. performed the in vitro experiments and analysed the data. D.S. performed
the adipose tissue histological analysis. G.S. made the catalytic-null-FTO construct. J.S.,
F.M., M.L. and S.U. assisted with technical aspects of the project. D.A. conducted the
animal experiments on FTO-4 mice. S.L., M.M., D.S., F.M.A. and R.D.C. wrote the paper.
D.S., F.M.A. and R.D.C. supervised the project.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Merkestein, M. et al. FTO inﬂuences adipogenesis by
regulating mitotic clonal expansion. Nat. Commun. 6:6792 doi: 10.1038/ncomms7792
(2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7792 ARTICLE
NATURE COMMUNICATIONS | 6:6792 | DOI: 10.1038/ncomms7792 | www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
